Short on time? Two Months in Two Paragraphs.

In August and September 2026, counterfeit medicines reached the most trusted points in the supply chain. In India, suspected fake cancer drugs were allegedly supplied to more than 90 Bengaluru hospitals, weeks after Delhi police arrested hospital employees in an oncology racket. Lab testing showed that black market retatrutide rarely contains what its label claims. One Australian lab matched only 1 of 18 samples, and one vial held a dangerous dose of semaglutide instead. Fake Botox put patients in hospitals in Montenegro and Ukraine. In the UK, criminals stopped copying brands and launched their own.

The common thread is that every trust signal was faked or bypassed. Batch numbers, expiry dates, certificates of analysis, CE markings and a LegitScript seal all failed to protect patients. The fakes caught early were caught on physical evidence, such as wrong fonts, oversaturated ink or a pack a patient thought looked different. Enforcement is rising, from pill press arrests in the US to tougher penalties proposed in Portugal and Nigeria. But detection still depends on someone noticing. Non-additive authentication closes that gap by reading what the genuine product already is, in seconds, from a photograph.

Counterfeit Medicine Roundup: August and September 2026

Two months, and one finding that kept coming back from the lab: the label was wrong.

In Australia, a vial sold as retatrutide held a massive dose of semaglutide instead. In New York, bodega vials of four different peptides contained none of the ingredients printed on them. In Bengaluru, cheap bulk drugs were allegedly poured into fresh vials and relabeled as premium imported cancer medicines. In Mexico, regulators flagged genuine-looking packs carrying altered expiry dates.

The package told one story. The contents told another. And in almost every case, nobody could tell until a patient was harmed or a sample reached a lab.

Here is what happened, and what it says about where the threat is going.

India’s cancer drug fakes reached the hospital pharmacy

India produced the biggest counterfeit story of each month, and both ran through hospitals.

On August 20, Delhi Police’s Crime Branch announced it had dismantled an interstate syndicate trafficking counterfeit and diverted anti-cancer medicines worth roughly Rs 9 crore. Seventeen people were arrested. Investigators recovered 588 filled vials and six empty ones, along with packaging material, registers and about Rs 50 lakh in cash. The seized products included Darzalex, Imfinzi, Erbitux, Gazyva, Bavencio, Adcetris and Keytruda.

Four of those arrested were employees of leading cancer hospitals. Police say the network stole drugs, vials and packaging directly from private hospitals to repackage counterfeit versions. It also moved genuine medicines diverted from hospitals and government warehouses. That means some of the product in this case was authentic, with authentic codes, moving through illegitimate hands.

Three weeks later, a second case surfaced in Karnataka. It began with an August 18 seizure of medicines and equipment worth about Rs 4.91 crore at an unauthorized facility near Bidadi. By mid-September, investigators believed the network had supplied suspected counterfeit cancer drugs, life-saving medicines and ICU injections to more than 90 hospitals and clinics in Bengaluru, often at discounts of around 50 percent.

Karnataka’s health minister described the alleged method: cheap bulk formulations repackaged in fresh vials and relabeled as premium imports. A pharmacy owner was arrested, a special investigation team ran searches in six states, and the state suspended an assistant drug controller accused of failing to inspect the pharmacy at the center of the case. Licenses of 17 distributors were suspended or canceled, including a local Pfizer depot. Investigators have stressed that the hospitals are not accused of knowingly buying fakes, and it is not yet known whether patients received them.

Two months, two cities, the same weak point. The fake did not arrive through a back alley. It arrived through procurement, at a discount, in packaging good enough to pass at a hospital pharmacy.

Retatrutide: the testing caught up with the hype

In June and July, the retatrutide story was warnings and harm reports. In August and September, the lab results arrived, and they were worse than the warnings.

An Australian drug testing laboratory analyzed 18 samples sold as retatrutide. Only one matched its label. Roughly 30 percent held more peptide than advertised, 30 percent held less, and one held none at all. The lab noted the peptide typically makes up about 10 percent of a vial’s contents, leaving the rest unaccounted for. Australian authorities say they have destroyed more than 94,500 unapproved peptide products this year.

In mid-September, an Australian patient was hospitalized with a torn esophagus after uncontrollable vomiting. Testing found the vial contained no retatrutide. It held an exceptionally high dose of semaglutide, the active ingredient in Ozempic. Australia has now recorded at least seven cases of acute liver injury linked to products sold as retatrutide.

The pattern held in the United States. After CBS News reported peptides being sold in New York bodegas, a laboratory found that four vials bought at a Brooklyn smoke shop did not match reference samples. In September, WIRED reporters bought and tested bodega vials of PT-141, NAD+, BPC-157 and retatrutide. None contained the active ingredient on the label, and the lab could not say what they did contain.

The first outcome data pointed the same way. A preprint study, still in peer review, compared black market retatrutide users with Eli Lilly’s trial participants. Trial participants lost 15.5 percent of body weight at one year. Black market users lost 7.2 percent.

Harm reports kept coming. UK doctors told the BBC that young, fit patients were arriving at hospitals, some with kidney failure. Irish hospitals warned against the drug after a patient injected by a personal trainer was admitted with vomiting and kidney disease. A Montana woman went into anaphylaxis within an hour of injecting a black market peptide, with her heart rate falling below 20 beats per minute.

Eli Lilly escalated. On August 12, it filed six lawsuits against online sellers, med spas and a compounding pharmacy. It then told investors it was pressing payment processors, e-commerce sites, shippers and social platforms to block sales, and issued similar warnings in Canada. In the UK, Lilly and Novo Nordisk announced joint efforts using court orders and social media takedowns. Dutch inspectors banned an online seller from marketing retatrutide, semaglutide and tirzepatide.

The trust signals failed too. CBS News found at least 35 businesses selling retatrutide and other peptides while displaying LegitScript certification. A seal meant to tell consumers a seller was legitimate became part of the sales pitch.

Counterfeiters started building their own brands

One September detail from the UK deserves more attention than it got.

The Medicines and Healthcare products Regulatory Agency froze more than £200,000 across three bank accounts tied to Alluvi Healthcare, following four raids that produced large seizures of illegal weight-loss drugs. An MHRA official told the BBC it was the first time he had seen suspected criminals create their own brand rather than copy an existing one.

That is a meaningful shift. A counterfeit of Ozempic can be compared against Ozempic. An invented brand has no genuine reference to fail against. It builds its own trust from scratch, with its own packaging, its own website and its own social following.

Ukraine showed the copied-brand version at scale. Authorities approved more than 250 searches in an investigation into counterfeit Biopatid, a tirzepatide weight-loss product. The batch was attributed to a manufacturer that the Partnership for Safe Medicines had already flagged as suspicious in US import records in 2025.

The paperwork is being faked as well. In August, a US federal judge sentenced the owner of a peptide company to 70 months for selling unapproved drugs. Prosecutors said the company used forged laboratory certificates to market research chemicals as high-purity and US-made. In September, a federal jury convicted a Texas man who sold misbranded and unapproved drugs through websites and a Facebook group under “research use only” labels, sending more than 10,000 shipments and collecting over $1.4 million.

When the brand, the certificate of analysis and the label can all be manufactured, the only thing left to check is the physical product itself.

The fakes that got caught were caught by their packaging

Across both months, the counterfeits that were stopped early were stopped by someone noticing that the pack looked wrong.

In August, Kenya’s Pharmacy and Poisons Board warned about a falsified batch of emergency contraceptives, batch T34197R, falsely attributed to Hungarian manufacturer Gedeon Richter. Two people were arrested. Every distinguishing feature the board listed was visual: a missing hot-melt tamper seal, oversaturated orange coloring, an incorrect logo, mismatched fonts on the authentication panel, and errors in the patient leaflet.

In September, authorities in Ho Chi Minh City warned of a potentially counterfeit batch of the hepatitis B drug Getino-B 300mg, batch 664F44. It was flagged because a patient noticed differences in the packaging. Kenya’s regulator then issued an alert on fake Lucentis eye injections, batches 18862110 and 18802112, and made an arrest.

On September 28, Mexico’s regulator Cofepris named falsified or tampered lots of Saizen, Bedoyecta and Buscapina Compositum, plus a Granulox wound spray flagged for an altered expiry date.

The list continued:

• Nigeria. NAFDAC Public Alert 037/2026 on August 9 warned of a suspected Pulmicort counterfeit sold as “Ulmicort.” In September, NAFDAC arraigned two men and a pharmaceutical firm over counterfeit Coartem malaria tablets that lab testing found contained no active ingredient.
• Maldives. The Food and Drug Authority warned against a counterfeit nivolumab batch, 8081399, following July’s WHO alert on falsified Darzalex.
• India. Misbranded Abhayrab rabies vaccines, batch KE25012, were seized in Delhi after failing a government potency test. Two people were booked in Lucknow over suspected fake Lipaglyn diabetes tablets, batch IB00327A. In Gujarat, officials seized 1,250 suspected counterfeit blood pressure tablets and inspected more than 30 businesses.
• Pakistan. Laboratory testing flagged nine cancer medicines as fake, substandard or unregistered, some with no active ingredient.

Notice how many of these alerts depend on a batch number. That works only after a fake is found and reported. Until then, the batch number on a counterfeit is usually a real one, copied from a genuine pack.

Fake Botox put patients in the hospital

Aesthetic injectables became one of September’s clearest harm stories.

Several women in Montenegro were hospitalized after receiving suspected counterfeit Dysport. Ukraine reported cases of botulism linked to cosmetic injections in three regions. Kuwait moved to block counterfeit Botox flagged through an INTERPOL alert. In August, Lebanese authorities in Beirut seized large quantities of smuggled and counterfeit Botox, dermal fillers and medicines, and Korean drugmakers moved against imported copycat aesthetic products.

In the United States, Massachusetts med spa owner Rebecca Fadanelli was sentenced to 46 months in federal prison for performing thousands of injections with counterfeit Botox and fillers imported from China and Brazil. Prosecutors said she falsely claimed to be a licensed nurse. Multiple clients were hospitalized with conditions including facial paralysis and infections.

Health Canada seized unauthorized injectables, including counterfeit Juvéderm, from an Ontario beauty lounge in August. In September it warned that counterfeit laser hair removal and therapy devices had been sold to Canadian clinics with falsified licenses.

The aesthetic market has the same ingredients as oncology: high prices, strong demand, buyers outside traditional pharmacy channels, and a product the end user cannot verify by looking at it.

Production moved closer to the patient

Nigeria’s regulator said out loud in September what the seizure data had been suggesting: counterfeiting is no longer only an import problem.

NAFDAC’s director of investigation and enforcement said Chinese-linked syndicates had shifted from shipping fakes into Nigeria to manufacturing and distributing them locally. The agency has begun closing illegal logistics facilities tied to the network. It reported 64 convictions of counterfeiters between June 2025 and June 2026, its highest ever, and put the value of fake and substandard goods seized or destroyed since 2023 at more than ₦1.54 trillion. Director-General Mojisola Adeyeye called for life imprisonment or the death penalty for offenders.

NAFDAC also reported removing 7,210 suspected fake, substandard or non-compliant products in a May to July surveillance sweep, 2,459 of them drugs and herbal products. In August, Nigerian police broke up a group repackaging counterfeit omeprazole, Viagra and Ampiclox, and Lagos police uncovered a distribution network allegedly operating across West Africa.

Thailand offered the same lesson in September. Police raided a counterfeit cough and allergy medicine operation and seized equipment and materials for up to 100,000 bottles. Investigators are still hunting the financier.

The border model still matters, though. In August, Tashkent customs seized more than 21 tons of a counterfeit antibiotic imported from China and falsely declared as Indian-made, the same week Uzbekistan intercepted 1,330 packages of counterfeits allegedly smuggled from Russia. Twenty-one tons is container freight moving through formal channels on falsified paperwork.

Local production and formal freight point to the same problem. In both, the fake is already inside the system before anyone has a reason to inspect it.

United States: pill presses, diversion and the compounding gray zone

The biggest US enforcement story went after the equipment, not the pills.

In September, federal agents arrested two principal managers and a former long-time employee of LFA Machines, a company that sells pill presses and tableting machines. An Arizona grand jury had indicted the company and the three men in August. Investigators allege they sold equipment knowing, intending, or having reasonable cause to believe it would be used to make counterfeit pills. The same month, the House unanimously passed the Stop Pills That Kill Act, which would require serialization of pill presses and key components and raise penalties for knowingly supplying equipment for illegal drug production.

Press seizures and sentencings continued in both months. A Massachusetts man got 21 years for a basement pill factory with two electric presses. A South Carolina man got more than 18 years for producing counterfeit pills on a press. A Michigan man was convicted over a stash house holding more than 160,000 pills and a press. Two Florida brothers were charged with selling counterfeit oxycodone containing nitazenes on the darknet after a fatal overdose in Virginia. On August 31, the Partnership for Safe Medicines reported press seizures across 13 states from February to July.

The chemistry inside fake pills kept changing. Cychlorphine, a newly documented synthetic opioid, has been linked to a rise in poisoning deaths after appearing in counterfeit pills. Fentanyl test strips cannot detect it.

Diversion and import cases rounded out the picture. A former operations manager at a New Jersey wholesale distributor was sentenced to 30 months for a scheme that fraudulently bought nearly $50 million in oncology and ophthalmology drugs for resale. CBP in Chicago intercepted a master carton shipment from China holding more than 10,000 tablets and 2,100 vials of unapproved medicines. In August, the Fourth Circuit upheld an injunction in Gilead’s case against alternative funding programs, finding that imported product lacking FDA track-and-trace information was materially different from the US version.

Compounding remained a gray zone where quality failures look a lot like counterfeiting to the patient. On September 18, the FDA warned Empower Pharmacy for producing large volumes of weight-loss drugs that were essentially copies of approved products, citing prescriber justifications repeated word for word. Three Texas compounders recalled glutathione injections for elevated endotoxin levels, and the FDA reported at least 30 adverse events tied to the first two recalls. Ohio’s pharmacy board suspended five facilities in September, including compounders shipping peptides that are not eligible for compounding.

A new eight-country consumer survey from Michigan State University’s Center for Anti-Counterfeiting and Product Protection found that one in five consumers had bought counterfeit medicines online, knowingly or not, often when the genuine drug was scarce.

Lawmakers and regulators tightened the rules

Several governments moved from case-by-case enforcement to structural fixes.

Portugal’s government began preparing legislation to make selling counterfeit drugs a specific criminal offense, closing a gap that had let the practice escape clear penalties. In the US, the Senate unanimously passed a bill in August allowing Customs and Border Protection to share data on suspected counterfeit shipments with rights holders, e-commerce platforms and carriers. The Partnership for Safe Medicines and the National Intellectual Property Rights Coordination Center formalized a joint investigative alliance.

At the state level, attorneys general from at least 19 states urged federal action on weight-loss drug ingredients from China linked to warehouses with ties to fentanyl production. Mississippi’s boards of nursing, pharmacy and medical licensure jointly told providers they may not compound, recommend or dispense “research-grade” peptides, and that patient waivers do not change that.

In the UK, the MHRA welcomed the sentencing of a man who supplied hospital medical devices, including neonatal feeding pumps, carrying invalid CE markings. The certification mark, like the batch number and the certificate of analysis elsewhere in this roundup, turned out to be just another thing that could be faked.

The through-line

Read across August and September and one thing stands out. Almost every trust signal in the supply chain was faked, borrowed or bypassed.

Batch numbers were copied from genuine packs. Expiry dates were altered. Certificates of analysis were forged. A LegitScript seal appeared on sellers breaking its rules. CE markings were invalid. In Delhi, the vials and packaging were genuine because they were stolen from hospitals. In the UK, criminals skipped the copy entirely and invented a brand of their own.

And behind every one of those signals, the contents were something else. A different drug. A wrong dose. No active ingredient at all.

The counterfeits that were caught early were caught on physical evidence: an oversaturated ink, a wrong font, a missing seal, a pack a patient thought looked different. That is the right instinct. It just cannot depend on a trained inspector or an alert patient happening to look closely on the right day.

This is the case for non-additive authentication. It does not add another code, seal or hologram for counterfeiters to copy. It reads what the genuine product already is: its artwork, print quality, color, typography and geometry. AI can compare those properties against the real thing in seconds, from an ordinary photograph, with no change to the packaging or the supply chain.

Every story above is a moment when someone could not tell the real from the fake fast enough. Closing that gap is the entire job.

Want to see how AI-powered, non-additive authentication protects your products and your patients? Talk to the TrueMed team.

Sources

• Delhi Crime Branch busts interstate anti-cancer drug racket, 17 arrested (ANI)
• 588 cancer drug vials seized in Rs 9 crore racket (Medical Dialogues)
• 17 held for selling counterfeit and diverted anti-cancer drugs (Indian Express)
• Bengaluru fake drug racket reaches 90+ hospitals (The Logical Indian)
• Fake cancer drugs and ICU injections supplied to over 90 Bengaluru hospitals (Business Standard)
• Karnataka minister on alleged method of fake drug racket (The Statesman)
• Bengaluru assistant drug controller suspended (The Hindu)
• Karnataka suspends distributor licenses including Pfizer depot (ThePrint)
• Australian lab finds dosing inconsistencies in black market peptides (ABC News)
• Fake retatrutide vial held semaglutide, patient suffers torn esophagus (ABC News)
• Seventh Australian liver injury case linked to black market peptide (ABC News)
• Brooklyn smoke shop vials fail identity testing (PR Newswire)
• Bodega peptide tests (WIRED)
• Preprint: Accelerating Use of Unapproved Retatrutide
• UK doctors warn on retatrutide side effects (BBC)
• Irish hospitals warn against illegal retatrutide use (Medindia)
• Fitness fans hospitalized after bootleg peptides (Forbes)
• Eli Lilly sues six companies over retatrutide sales (Reuters)
• Lilly calls on platforms and payment companies to act (Eli Lilly)
• Eli Lilly Canada warning on retatrutide (Eli Lilly Canada)
• Novo Nordisk and Lilly act on UK counterfeits (Financial Times)
• Dutch inspectors ban webshop selling weight-loss drugs (DutchNews)
• LegitScript-certified sites selling retatrutide (CBS News)
• Alluvi Healthcare bank accounts frozen (BBC)
• Ukraine counterfeit Biopatid investigation (UkrMedia)
• Peptide vendor sentenced to 70 months (CBS News)
• Texas man guilty of selling misbranded drugs online (DOJ)
• Kenya alert on counterfeit emergency contraceptives (Streamline Feed)
• Vietnam warning on suspected counterfeit hepatitis B drug (Vietnam.vn)
• Kenya alert on fake Lucentis injections (People Daily)
• Cofepris names counterfeit lots (The Rio Times)
• NAFDAC Public Alert 037/2026 on counterfeit Pulmicort (DrugsControl)
• NAFDAC arraigns firm over counterfeit Coartem (Real News Magazine)
• Maldives warning on counterfeit nivolumab (Edition.mv)
• Misbranded rabies vaccines seized in Delhi (Business Standard)
• Spurious Lipaglyn racket busted in Lucknow (ThePrint)
• Ahmedabad fake blood pressure tablet crackdown (The Blunt Times)
• Pakistan lab flags nine cancer drugs (The Express Tribune)
• Montenegro patients hospitalized after fake Dysport (Srpske)
• Ukraine botulism cases linked to beauty injections (UkrMedia)
• Kuwait warns against counterfeit Botox (Arab Times)
• Lebanon busts counterfeit medical products operation (Lovin Beirut)
• Korean drugmakers move against copycat aesthetic medicines (Chosun Biz)
• Med spa owner sentenced for counterfeit Botox (DOJ)
• Health Canada seizes unauthorized injectables (Health Canada)
• Counterfeit laser hair removal devices found in clinics (Health Canada)
• NAFDAC on local production of fake products (Vanguard)
• NAFDAC links fake products to Chinese networks (BrandSpur)
• NAFDAC DG calls for stiffer penalties (allAfrica)
• NAFDAC removes 7,210 products in three months (The Sun Nigeria)
• Police bust fake drug syndicate (Vanguard)
• Lagos police bust counterfeit drug syndicate (Vanguard)
• Thai police hunt financier behind counterfeit cough medicine ring (The Straits Times)
• Tashkent customs seize 21 tons of counterfeit medicines (Kun.uz)
• Uzbekistan seizes counterfeit drugs smuggled from Russia (UzDaily)
• LFA Machines indictment and arrests (DOJ)
• Stop Pills That Kill Act, H.R. 8005 (Congress.gov)
• Massachusetts man sentenced to 21 years for pill factory (DOJ)
• South Carolina man sentenced to more than 18 years (DOJ)
• Michigan man convicted in fentanyl pill operation (Macomb Daily)
• Jacksonville brothers charged with nitazene distribution (DOJ)
• PSM pill press update, February to July 2026
• Cychlorphine linked to counterfeit pill deaths (Social Media Victims Law Center)
• New Jersey distributor manager sentenced in diversion scheme (DOJ)
• CBP Chicago intercepts unapproved medicines (CBP)
• Fourth Circuit ruling in Gilead case (CNBC)
• FDA warning letter to Empower Pharmacy (FDA)
• Centric Compounding glutathione recall (FDA)
• FDA reminder on supplement-grade glutathione (FDA)
• PSM weekly roundup, September 21, 2026 (Ohio board suspensions)
• A-CAPP global consumer survey on buying medicines online (Michigan State University)
• Portugal to criminalize sale of counterfeit drugs (The Portugal News)
• Senate passes bill to combat counterfeit imports (Senator Hassan)
• IPR Center and PSM alliance (IPR Center)
• State attorneys general letter on weight-loss ingredients from China (Iowa AG)
• Mississippi boards’ joint peptide statement
• MHRA welcomes sentencing over falsely certified devices (GOV.UK)

Here is an uncomfortable way to think about your anti-counterfeiting program. Every hologram, every security ink, every tamper-evident seal, every printed code you have ever added to a pack is, from the counterfeiter’s side of the table, a specification document. It tells them precisely what they need to reproduce in order to be believed. You wrote the acceptance criteria and then published them on every carton you shipped. 

That is not an argument for doing nothing. It is an argument that the pharmaceutical industry has spent forty years and an enormous amount of money playing a game whose rules guarantee it will keep losing ground, and that the way out is not a better feature. It is a different model entirely. 

The numbers say the losing is real. The Pharmaceutical Security Institute recorded 2,857 distinct medicines counterfeited, diverted, or stolen in 2025, an eighteen percent increase on the previous year, with criminal groups targeting 756 medicines across sixteen therapeutic areas. In May 2026, an INTERPOL-coordinated operation across ninety countries seized 6.42 million doses of unapproved and counterfeit pharmaceuticals worth USD 15.5 million and shut down roughly 5,700 websites and social media channels selling them. Europol’s Operation SHIELD VI produced 3,354 prosecutions and EUR 33 million in seizures across thirty countries. Enforcement is working harder than it ever has, and the problem is still growing. 

So the question worth asking is not how counterfeiters are getting better. It is why the defenses keep failing in the same way. 

Why pharmaceutical crime happens at all 

In 1979, criminologists Lawrence Cohen and Marcus Felson published an argument that changed how crime prevention is understood. Crime, they said, does not require an increase in criminality. It requires three conditions to converge in the same place at the same time: a motivated offender, a suitable target, and the absence of a capable guardian. Remove any one and the crime does not happen, no matter how motivated the offender is. 

Applied to pharmaceutical brand protection, the framework is unusually clarifying, because it sorts your options into things you can change and things you cannot. 

The motivated offender is fixed. Counterfeit pharmaceutical operations are organized, financed, and technologically capable. In July 2026 alone, Indian enforcement agencies raided a licensed-looking facility in Bazpur that was manufacturing counterfeit medicines under the names of Sun Pharma, Macleods, Intas, and Steadmed, and recovered packaging machinery, wrappers, and government-issued excise holograms on the premises. Days later, another operation in Dehradun turned up an Alu-Alu packing machine, a strip machine, an inkjet belt printer, and printed aluminum foil and master cartons for major brands. These are not people scraping labels off bottles in a garage. They are production lines. No brand owner is going to reduce the global supply of them. 

The suitable target is also fixed, and this is where it gets genuinely awkward. A suitable target is something valuable, portable, in demand, and accessible. Every medicine you sell qualifies, and the better it sells the more qualified it becomes. GLP-1 therapies are the clearest illustration in living memory: a category so commercially successful that it created its own counterfeit industry within a couple of years. You cannot make your product less valuable to fix this. Commercial success and counterfeit exposure are the same curve. 

Which leaves one condition. Guardianship. The presence of something that makes the crime harder to complete or more likely to be caught. It is the only side of the triangle a pharmaceutical company actually controls, which means every budget line and every hour your brand protection function spends is, in effect, spent there. That makes it worth being brutally honest about how well it has been spent. 

The specification problem 

Physical security features share a structural flaw that no amount of engineering fixes. They work by adding something to the package that is supposedly hard to reproduce. Hard is not impossible, and the history of the category is a history of features being replicated within months of launch. The Bazpur raid makes the point more bluntly than any vendor slide could: official excise holograms, the kind meant to signal government verification, were sitting in a counterfeit manufacturing facility alongside the packaging machinery. 

When a security feature is replicated, it does not simply stop working. It starts working for the other side. A pharmacist trained to check for a hologram, who finds a hologram, concludes the product is genuine. The guardian has not gone missing. It has been impersonated, and the impersonation is more dangerous than the absence would have been, because it converts scrutiny into false confidence. 

There is an economic version of the same trap. Added features are priced per unit. Every hologram, every security label, every microtext printed, every serialized code is a cost that scales with volume, forever, on every pack you ship, in every market you enter. The counterfeiter’s cost of copying that feature does not scale the same way. They pay once to solve it and then reproduce it as cheaply as you do. You are buying protection on a per-unit meter against an adversary who bought the answer outright. 

What a serial number actually proves 

Serialization deserves a more careful hearing than it usually gets from anti-counterfeiting vendors, ourselves included. Track and trace infrastructure has genuinely improved supply chain visibility, and DSCSA and the EU Falsified Medicines Directive have made diversion meaningfully harder to conceal. Serialization is not a failure and it is not going away. 

But it is worth being precise about what a serial number proves. A code proves that a code exists in a database. It does not prove that the physical object carrying it came out of your plant. Codes can be duplicated, harvested from discarded packaging, or printed onto a repackaged pack holding something else entirely. 

In April 2025, the FDA seized counterfeit Ozempic that had reached the legitimate United States supply chain carrying an authentic lot number, PAR0362, paired with a counterfeit serial number. In December 2025, the agency seized more counterfeit Ozempic, again inside the legitimate supply chain, this time labeled with lot number PAR1229, which was itself an entirely authentic lot number. The way to tell the fake from the real product was not the code. It was the position of the EXP/LOT text on the pen label, which sat to the left of the expiry date on the counterfeit and above it on the genuine article. 

Read that again, because it is the whole argument in one case study. The most heavily serialized, most tightly regulated pharmaceutical supply chain in the world, running a product from one of the most sophisticated manufacturers in the industry, and the distinguishing feature was print layout. Millimeters of typography. Not the code. The printing. 

Laboratory testing catches these things, but slowly. Samples are collected, shipped, queued, and analyzed while the rest of the consignment keeps moving. Guardianship that arrives three weeks late is not guardianship. It is documentation of a failure that already happened. 

What capable guardianship actually requires 

If guardianship is the only variable you control, it is worth defining what a capable one looks like. Three properties do most of the work. 

It has to be present where the product is. A capability that exists only in a central laboratory is, by definition, absent everywhere else, and absent guardianship is the precondition for the crime. Verification has to function in a distributor’s warehouse in Lagos, at a customs desk in Rotterdam, in a pharmacy in São Paulo, and in a patient’s kitchen. That means it cannot depend on specialist hardware, controlled lighting, or a trained analyst being in the room. 

It has to be fast enough to change an outcome. There is a hard line between knowing before the product is dispensed and knowing afterward. One prevents harm. The other records it. 

And it cannot be something the counterfeiter can reproduce. This is the property almost every legacy approach fails, and it is why the distinction between additive and non-additive authentication is a difference in kind rather than degree. 

Non-additive authentication: verifying what was never added 

If what you verify is something you added, it can be copied. If what you verify is the product’s own inherent characteristics, there is no added feature to replicate. 

That is the design principle behind TrueMed. The platform adds nothing to the product, the pack, or the process. It authenticates by analyzing what is already there: exact dimensions and shape, precise color values in both CMYK and RGB, typography and character placement, gradients, graphics, logos and vector artwork, and print quality measured at a resolution the human eye cannot resolve. It reads full secondary packaging, blister packs, and it identifies sophisticated counterfeits, diverted stock, and repackaged or relabeled product. 

To defeat that, a counterfeiter would have to reproduce your actual manufacturing process rather than your security feature, at which point the economics that made the crime attractive have already collapsed. 

The three properties above are engineering requirements, and they shape what the platform looks like in practice: 

• Present where the product is. Verification runs from a standard smartphone camera, a tabletop scanner, an upload portal, or any other digital image source, which covers the overwhelming majority of real-world conditions. Investigators use the Digital Field app, patients use the consumer app, and partners can submit images by emailed link. Every capture routes to the same place. 

• Fast enough to matter. Analysis is automated and returns a result while the product is still in front of the person holding it, not weeks later in a report. 

• Nothing added, so nothing to copy. No holograms, no inks, no substrate changes, no new artwork, no line modification. Which also means no per-unit cost, and no gap between the markets where you deployed the feature and the markets where you did not. 

The Ozempic case is the accidental proof. Investigators caught the counterfeit on a print characteristic. TrueMed makes that kind of analysis systematic and automated instead of depending on a trained specialist noticing a millimeter under good light on a good day. 

From detection to protective intelligence 

There is a final consequence of taking the triangle seriously, and it is the one that matters commercially. 

Detection treats every counterfeit as an isolated incident to be caught. It produces a pile of individually resolved cases and no cumulative advantage. Intelligence treats each one as a data point about an operation. 

Every scan, wherever it happens in the world, sends its result back to the Digital Forensic Lab. Cases are assigned a TrueMed ID and every step is logged, so what comes out is timestamped, scan-level visual evidence with an intact chain of custody, the kind of file a customs officer or a prosecutor can actually act on. Across thousands of scans, that same data becomes a picture rather than a pile: strain analysis linking a new seizure to previous ones, decoded 2D matrix codes and GTIN, LOT and expiry data, geographic mapping of where fakes surface and where genuine stock is turning up outside its intended market, and price analysis that flags diversion before it looks like counterfeiting. 

That is the difference between knowing you have a counterfeit problem and knowing whose it is, where it originates, and which route it travels. 

And it changes the offender’s arithmetic, which detection alone never does. Counterfeiting is a business, run by people making rational calculations about cost, risk, and return, and rational operators respond when those inputs move. When a brand can verify product anywhere in the world, produce court-ready evidence in minutes rather than weeks, connect a new case to prior ones, and hand enforcement a file strong enough to prosecute, targeting that brand becomes slower, more expensive, and considerably more likely to end in an arrest. 

Counterfeiters have finite capacity and an effectively unlimited choice of targets. Applied consistently, capable guardianship does not just catch more fakes. It makes your products the option they skip. 

Becoming an unsuitable target 

That is what it means to become an unsuitable target. Not that your medicine got less valuable, and not that the criminals went away, but that the third condition their business model depends on is no longer available wherever your products are. The triangle stops closing. There is no opportunity left to act on. 

You cannot out-engineer a counterfeiter on features, because features are instructions. You can make yourself the target that is not worth the trouble. 

How suitable a target are you right now? 

The Counterfeit Risk Profiler takes about three minutes. Eleven questions, scored across the three dimensions that determine exposure: how attractive your product is to counterfeiters, how vulnerable your supply chain is, and how severe the patient impact would be if a fake reached a patient. 

Profile your risk 

Or see how non-additive authentication works on your product and packaging, and what the Digital Forensic Lab produces when a case needs to stand up in court. 

Sources 

1. Cohen, L. E. and Felson, M. (1979). Social Change and Crime Rate Trends: A Routine Activity Approach. American Sociological Review, 44(4), 588–608. https://www.ojp.gov/ncjrs/virtual-library/abstracts/social-change-and-crime-rate-trends-routine-activity-approach 

2. Pharmaceutical Security Institute data, cited in Pfizer, Combating Counterfeit Medicine. https://www.pfizer.com/products/medicine-safety/counterfeiting 

3. INTERPOL (May 2026). Global crackdown on illicit pharmaceuticals sees USD 15.5 million in seizures. https://www.interpol.int/en/News-and-Events/News/2026/Global-crackdown-on-illicit-pharmaceuticals-sees-USD-15.5-million-in-seizures 

4. U.S. Food and Drug Administration. FDA warns consumers not to use counterfeit Ozempic (semaglutide) found in U.S. drug supply chain, updates of 14 April 2025 and 5 December 2025. https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-consumers-not-use-counterfeit-ozempic-semaglutide-found-us-drug-supply-chain 

5. Medical Dialogues (20 July 2026). Bogus medicine factory using reputed pharma brands busted in Uttarakhand. https://medicaldialogues.in/news/industry/pharma/bogus-medicine-factory-using-reputed-pharma-brands-busted-in-uttarakhand-175394 

6. TrueMed. June–July 2026 Counterfeit Drug News Roundup. https://truemedinc.com/blogs/ 

7. Partnership for Safe Medicines (May 2026). Safety risks in the GLP-1 market. https://www.safemedicines.org/2026/05/glp-1-safety-risks-may-2026.html 

World Health Organization. Substandard and falsified medical products. https://www.who.int/news-room/fact-sheets/detail/substandard-and-falsified-medical-products 

For most of the history of counterfeiting, the counterfeiter’s biggest constraint was craft. Faking a convincing hologram, matching a specific ink, reproducing a precise print run. These took skill, equipment, and time. That constraint is disappearing.

Over the past two years, investigators and brand-protection teams have documented a clear shift: counterfeiters are using generative AI to reproduce authentic pharmaceutical packaging with startling accuracy, spin up convincing fake pharmacy websites, and even manipulate search rankings so those sites appear ahead of legitimate ones. Legal and brand-protection analysts have flagged the same pattern. Greenberg Traurig’s 2026 brand-protection analysis notes that counterfeiters increasingly use AI tools to reproduce a brand’s distinctive packaging design itself, then apply different marks to it, banking on consumers recognizing the packaging and assuming the product inside is genuine. On the physical side, low-cost printing is being used to fabricate blister packs and packaging components that once required specialized tooling.

The uncomfortable truth is that the tools that make design and manufacturing cheaper and faster for legitimate businesses make counterfeiting cheaper and faster too. The barrier to producing a convincing fake has collapsed.

Why Traditional Pharmaceutical Anti-Counterfeiting Technology Is Failing

Most anti-counterfeiting technology deployed over the last two decades rests on a single assumption — add a visible feature that’s hard to copy, and hope people check it. Holograms in the 1990s. Color-shifting inks. Microtext. QR codes.

Every one of these has now been beaten, and generative AI accelerates the defeat. An AI model can study authentic packaging, understand the visual effect of a security feature, and help a counterfeiter reproduce it before the first sheet is even printed. A feature that takes a brand months and real money to deploy can be approximated by a criminal in an afternoon.

How Big Is the Pharmaceutical Counterfeiting Problem

The numbers make the urgency concrete:

• The World Health Organization estimates that 1 in 10 medical products in low- and middle-income countries is substandard or falsified, costing countries an estimated $30.5 billion per year (WHO, Substandard and Falsified Medical Products fact sheet).
• INTERPOL’s most recent global sweep, Operation Pangea XVIII (March 2026), spanned 90 countries and territories, led to 269 arrests, dismantled 66 organized criminal groups, and seized roughly 6.42 million doses of unapproved or counterfeit medicine worth an estimated $15.5 million (INTERPOL press release). The prior edition, Pangea XVII, was even larger — 50.4 million doses seized and 769 arrests — highlighting how much volume is moving through this trade.

That’s a serious result, and it also tells you how much is out there to be found. Seizures happen after products are already in circulation. Enforcement, though impressive in scale, remains fundamentally reactive.

How AI Counterfeit Pharmaceutical Detection Works

If counterfeiters have industrialized imitation, the defense can’t be a static feature bolted onto packaging. It has to be adaptive, it has to learn, and it has to verify the actual product rather than a proxy for it.

This is where AI authentication changes the equation. But the kind of AI matters enormously.

A counterfeiter’s generative model is trying to reproduce what a product looks like. TrueMed’s patented technology is trained to detect the difference between authentic and fake at a level of precision the human eye can’t match, analyzing typography, color, gradients, logos, print quality, and micro-defects across a product and its packaging. 

Reproducing a look is one thing. Reproducing the full, consistent fingerprint of a genuine manufacturing process, down to details the counterfeiter doesn’t even know are being measured, is another entirely.

Three properties make this durable against an AI-equipped adversary:

1. It verifies the product, not a code. A cloned QR code passes a code check. It does not pass an analysis of the physical artifact itself.
2. It learns. As counterfeiters adapt, the detection models are retrained on new examples. Every analyzed fake makes the system better at catching the next one — the same feedback loop that makes the counterfeiters dangerous, turned back against them.
3. It’s non-additive and instant. Because TrueMed adds nothing to the product, there’s no security feature for a counterfeiter to reverse-engineer and reproduce. Authentication happens from an ordinary image in minutes, which means it can happen everywhere — at customs, in a warehouse, at a pharmacy counter, in a patient’s hand.

Final Thought: The Race Won’t End. The Advantage Can Shift.

No one should promise that counterfeiting will be “solved.” It’s a moving target with motivated, well-funded adversaries who now have the same generative tools everyone else does. The realistic goal is to make counterfeiting so hard, so expensive, and so likely to be caught that it stops being worth the effort.

That happens when authentication moves upstream — continuous, learning, and focused on the product itself — rather than sitting on the packaging waiting to be copied. 

The counterfeiters have brought AI to the fight. The brands that win will be the ones who bring the better AI.

FAQ

How are counterfeiters using AI to fake pharmaceutical packaging?
Generative AI models study high-resolution images of authentic packaging and reproduce logos, typography, color-shifting inks, and even holograms, cutting the time and skill counterfeiting once required.

What makes AI-based authentication harder to defeat than traditional security features?
Traditional features are static and visible, so they can be studied and copied. TrueMed instead analyzes the manufacturing fingerprint of the physical product, details a counterfeiter doesn’t know are being measured.

How big is the counterfeit medicine problem globally?
The WHO estimates 1 in 10 medical products in low- and middle-income countries is substandard or falsified. INTERPOL’s Operation Pangea XVIII seized 6.42 million doses across 90 countries in March 2026 alone.

How can pharmacies or distributors verify a medicine is authentic?
With TrueMed, by checking the physical product itself, an ordinary photo taken at receiving, stocking, or dispensing is enough to confirm authenticity in minutes.

Does AI-based authentication require changing packaging or adding a security feature?
No. TrueMed verifies the product’s manufacturing fingerprint directly, so nothing is added to the package, leaving no new feature for a counterfeiter to copy.

Can AI counterfeit detection improve over time?
Yes. TrueMed’s models retrain on every new counterfeit analyzed, so accuracy improves as tactics evolve, unlike static features that weaken the longer they’re in use.

TrueMed builds AI that detects counterfeit medicines instantly, without adding anything to the product. Learn more at truemedinc.com.

Counterfeit Medicine Roundup: June and July 2026

Two months, four continents, and one theme that kept repeating: the fake product looked right.

That is the thread running through almost everything that happened across June and July. A tablet with a convincing imprint. A vial with a real batch number. A pen with the correct label. A website that looks like a pharmacy. In case after case, the only thing standing between a patient and a counterfeit was a visual judgement that nobody was equipped to make.

Here is what happened, and what it says about where the threat is going.

Europe put a number on the fake-pill problem

On 9 June, the European Union Drugs Agency published its European Drug Report 2026, and buried in it was one of the more alarming trend lines of the year. Counterfeit tablets containing nitazenes, a class of synthetic opioids that can be far more potent than heroin, are spreading fast. Ten European countries seized more than 50,000 nitazene-containing tablets in 2024. In 2023 the figure was 23,000. In 2022 it was 380.

The tablets are made to resemble prescription medicines, most often oxycodone, and to a lesser extent benzodiazepines such as diazepam and alprazolam. The agency’s own framing is the important part: the authentic appearance of these products creates a false sense of security. People taking them may have no idea they are consuming a synthetic opioid at all, and the EUDA warned that the tablets may spread to groups with no opioid tolerance, including young people.

The report landed alongside Europol’s Operation SHIELD VI enforcement results and a joint EUDA, Europol and European Medicines Agency public awareness campaign, “Stay on Top – EU vs Fake Medicines,” urging consumers to buy only from authorised sources.

That is the right message. It is also an incomplete one, because “buy from authorised sources” does not help when the counterfeit is already sitting inside a legitimate supply chain, which is exactly what happened repeatedly over these two months.

Retatrutide became the defining counterfeit story of the summer

If one product dominated the news cycle across June and July, it was a drug that does not legally exist yet.

Retatrutide is an experimental weight-loss compound still in clinical trials, not approved by any regulator anywhere in the world. It has nevertheless become one of the most widely trafficked pharmaceutical products on the internet, and the harm reports piled up quickly.

In the United Kingdom, MHRA records reported by the Daily Mail showed a man died in 2025 after taking retatrutide, with reported side effects up roughly 350 percent in 2026 compared with all of 2025, including eight suspected liver, gallbladder, pancreas and bile duct complications. One patient with acute liver failure was considered for a transplant before being stabilised.

Australian health officials issued warnings in late June after multiple cases of severe illness linked to products sold as retatrutide, including acute liver failure, kidney injury and hospitalisations, sourced through social media, beauty clinics and online sellers. Australia’s Therapeutic Goods Administration launched a wider crackdown on unapproved peptides on 10 June. New Zealand’s Medsafe followed with its own consumer advisory. Malta warned the public in mid-June. In the Netherlands, hospitals reported two people falling into comas after taking counterfeit weight-loss drugs bought online that contained only insulin. Denmark reported a sharp increase in poisonings from counterfeit weight-loss products.

In the United States, CBS News found more than 120 websites and dozens of clinics and med spas openly advertising or prescribing the drug, and reported that exposures to America’s Poison Centers had climbed to an average of 95 cases a month in early 2026, a 265 percent increase over late 2025. In July, CBS reporters bought a vial labelled as retatrutide from a New York City bodega for 95 dollars, with no age verification, no questionnaire and no prescription. The Partnership for Safe Medicines found that roughly 15 pounds of retatrutide entered the US between January and April 2026.

Two data points frame why any of this matters for authentication. First, a study of self-reported side effects among Reddit users found symptom patterns that diverged sharply from Eli Lilly’s clinical trial data, a discrepancy the researchers noted may simply mean that much of what is sold as retatrutide is not retatrutide. Second, an analysis of consumer-submitted samples from a peptide testing facility found that 71 percent of grey-market samples failed to meet FDA manufacturing standards, 15 percent contained measurable bacterial endotoxins, and 2 percent did not contain the peptide on the label at all.

Blockchain analytics firm Chainalysis put the crypto-powered grey-market peptide trade at more than 100 million dollars a year, and linked some overseas suppliers to Chinese chemical manufacturers that previously sold fentanyl and amphetamine precursors. Those firms did not exit the criminal economy. They changed product lines.

Cancer drugs kept turning up

On 4 June, sources confirmed to the International Consortium of Investigative Journalists that Mexican federal authorities had seized vials labelled as Keytruda during an operation to dismantle a counterfeit ring outside Mexico City. It was the second such operation involving vials bearing Keytruda labels. The same joint action recovered 15,000 doses of clonazepam, more than 100 counterfeit vaccines and 1,000 vaccine labels.

In early July, the World Health Organization issued a warning after batches of counterfeit Darzalex, a bone marrow cancer treatment, were found in the Maldives. Myanmar’s regulator warned of counterfeit Albutein 20% Solution circulating in the country, identifiable in part by an incorrect “IP Specification” label and a missing national registration number. Kenyan authorities warned about a counterfeit batch of the breast cancer drug Phesgo, distinguishable because the fake contained a white powder rather than the ready-to-use liquid of the genuine product.

The pattern is consistent with what ICIJ’s earlier Cancer Calculus investigation described: high-priced oncology medicines create a price gap, the price gap creates demand for cheaper supply, and criminal networks fill it using authentic batch numbers and refilled vials. When the fake carries a real lot number, serialisation alone does not resolve the question.

India ran a near-continuous enforcement campaign

Indian authorities logged counterfeit medicine actions at a rate of several per week through July.

In Puducherry, a sting operation shut down a facility producing fake Pregabalin-150 tablets as part of an international network, with 300,000 counterfeit tablets and packaging materials seized and the owner arrested. Haryana’s FDA busted a racket supplying spurious Telma-AM, a widely prescribed blood pressure combination, arresting two on 20 July; a follow-up joint raid with Delhi authorities two days later recovered a further 560 fake blister packs and uncovered an unlicensed warehouse.

Uttarakhand’s Special Task Force raided a factory in Bazpur producing spurious allopathic medicines without a licence, seizing packaging machinery and excise holograms alongside the drugs. A separate raid in Dehradun on 23 July uncovered another counterfeit manufacturing unit stocked with fake versions of leading pharma brands and their packaging material. Uttar Pradesh’s FSDA exposed an interstate network in Meerut and Baghpat that was packaging food supplements as the life-saving drug Evion 400.

Late July brought more: a fake drug and anabolic steroid manufacturing setup inside a residential apartment in Delhi’s Narela, uncovered in a two-day joint operation involving Haryana FDA and Delhi Police, and a large cache of suspected counterfeits seized in Gaya, Bihar. In Gurgaon, a court denied bail to the accused ringleader of a counterfeit Mounjaro operation dismantled in April.

The recurring detail worth noting is the packaging machinery. These are not crude operations. They are production lines with the equipment to make convincing artwork, and the holograms seized in Uttarakhand make the point better than any statistic: the security feature was manufactured on site.

Nigeria escalated on every front at once

Nigeria had one of the busiest months of any single country.

On 15 July, the Nigeria Customs Service announced the interception at Apapa Port of fake NAFDAC-labelled medicines, illicit drugs and expired pharmaceutical products with a combined duty paid value of ₦53.39 billion. The consignment initially appeared legitimate; the giveaway was a NAFDAC certificate that verification showed to be fraudulent. The same day, traders at the Bridge Head Drug Market in Onitsha handed over 192 consignments of substandard, falsified and expired medicines worth ₦435 million to NAFDAC for destruction, recovered through surveillance in the market between December 2025 and June.

NAFDAC issued Public Alert 036/2026 on 21 July over suspected counterfeits mimicking AstraZeneca’s Forxiga (dapagliflozin), detected in eastern Nigeria under the near-identical names “Forzigar” and “Foziga” and imitating the AstraZeneca logo. In June, Enugu State’s health ministry warned that counterfeit Augmentin 625mg tablets were circulating, closely resembling the genuine GSK product and carrying the same batch number, AC3N.

On the legislative side, the Senate advanced the Counterfeit Medical Products, Fake Drugs and Unwholesome Processed Foods (Prohibition and Control) Bill 2026, which proposes 15-year jail terms, asset forfeiture, victim compensation and expanded NAFDAC enforcement powers, explicitly citing online drug sales, cross-border trafficking and increasingly sophisticated counterfeiting methods as the reason the existing law needs replacing.

Elsewhere in the region, Liberia’s Medicines and Health Products Regulatory Authority seized counterfeit and substandard medicines worth around L$400,000 in Bong County and launched a five-year regulatory strengthening plan on 25 June.

Enforcement and sentencing in the United States

Four Massachusetts men were sentenced to between 12 and 18 years for running a counterfeit pill operation that used five industrial pill presses and pharmaceutical-mimicking imprint tooling to produce fakes of oxycodone, Adderall and Xanax containing fentanyl, methamphetamine or bromazolam. Prosecutors linked the scheme to more than a dozen deaths.

Two New York defendants were convicted for operating industrial-scale pill pressing machines and selling the output as prescription medication to victims in all 50 states. In New Jersey, further members of a nine-person trafficking organisation were sentenced for importing fentanyl analogues from China and pressing them into counterfeit prescription pills; five of the nine have now received a combined 685 months.

A forensic laboratory in north Louisiana warned in July that nearly one in three street tablets bearing legitimate-looking drug imprints tested as counterfeit, with fentanyl the most common substance found and blue M30 tablets the most commonly faked. Their deputy director of toxicology put it plainly: the stamps look authentic, so you probably cannot tell the difference.

Three bipartisan bills targeting pill press equipment advanced to full committee in Congress: the Fight Illicit Pill Presses Act, the PRESS Act, and the Stop Pills That Kill Act. And in early July, Alibaba and its payment subsidiary agreed to pay 600 million dollars to settle Department of Justice allegations that their platform facilitated sales of illicit medications, precursor chemicals and counterfeit pill-making equipment between 2016 and 2024.

Regulators reached for verification systems

Several governments responded structurally rather than case by case.

Pakistan’s federal cabinet approved a nationwide pharmaceutical track-and-trace system aimed at eliminating counterfeit and substandard medicines. Ukraine registered its National Organization for the Verification of Medicinal Products, a step toward a national verification system using 2D coding to authenticate packaging and align with European standards.

In the UK, the MHRA, Advertising Standards Authority and General Pharmaceutical Council issued a joint warning against advertising unlicensed weight-loss medicines or prescription-only GLP-1 products to the public. The MHRA strengthened safety warnings for botulinum toxin type A products following rare botulism cases, noting that unlicensed and counterfeit versions are especially dangerous. Four members of a criminal group that sold almost two million doses of unauthorised prescription medicines online were sentenced to nearly 15 years combined following MHRA’s Operation Lamborghini.

British experts also warned of an expected surge in counterfeit weight-loss pills now that Wegovy in tablet form has entered legitimate supply chains. Pills, they noted, are far easier for criminals to copy than injectables, and fakes made from chalk and paint can be nearly undetectable by eye. The UK regulator has seized more than 6,500 fake weight-loss products in the past three years. Counterfeiters have cloned legitimate UK pharmacy websites, and discounts on fake injections have been kept modest specifically to avoid arousing suspicion. The chair of Parliament’s health and social care committee said publicly that she has very little confidence the MHRA can protect the country against counterfeit drugs at current resourcing.

Tajikistan rounded out the international picture, dismantling an operation producing fake versions of paediatric and over-the-counter medicines including Nurofen and Paracetamol, seizing tens of thousands of bottles along with packaging materials and raw ingredients.

The through-line

Read across two months and the shape is unmistakable.

The products being faked now span the full range: opioid analgesics, blood pressure combinations, antibiotics, epilepsy drugs, oncology biologics, plasma proteins, children’s fever medicine, vitamin supplements and weight-loss injectables. The channels span the full range too: bodegas, social media, cloned pharmacy websites, wholesale consignments through major ports, and licensed hospitals in at least four countries.

And the defence, almost everywhere in these stories, was a person looking at a package and deciding whether it seemed right. A customs officer looking at a certificate. A pharmacist looking at a strip. A patient looking at a pen.

That defence failed in Kota, in Mexico City, in the Maldives, in Lagos, in Northampton, in Amsterdam. It failed not because the people involved were careless, but because the fakes were manufactured on real equipment with real batch numbers and near-perfect artwork. When the counterfeiter has the packaging machine and the hologram press, the security feature stops being a security feature. It becomes a set of instructions.

This is the case for a different model. Authentication cannot depend on what a person can notice, and it cannot depend on features that can be copied along with everything else. It has to work from properties the product already has: the artwork, the print quality, the colour, the typography, the geometry, the microscopic signature of how a genuine package was actually produced. AI can read those in seconds from an ordinary photograph, with no sticker, no code, no hardware and no change to the supply chain.

That is what non-additive authentication means, and it is why TrueMed exists. Every story above is a story about a moment when someone could not tell the real from the fake fast enough. Closing that gap is the entire job.

Want to see how AI-powered, non-additive authentication protects your products and your patients? Talk to the TrueMed team.

Sources

• EUDA, European Drug Report 2026 – new health risks in a fast-moving drug market: https://www.euda.europa.eu/news/2026/new-health-risks-europeans-fast-moving-drug-market_en
• EUDA, new psychoactive substances and fake medicines containing nitazenes: https://www.euda.europa.eu/publications/european-drug-report/2026/new-psychoactive-substances_en
• Counterfeit opioid tablets seized across Europe (IBTimes UK): https://www.ibtimes.co.uk/counterfeit-opioid-crisis-europe-2024-1802066
• Mexico seizes suspicious Keytruda in counterfeit ring raid (ICIJ): https://www.icij.org/investigations/cancer-calculus/mexico-seizes-suspicious-keytruda-in-raid-to-dismantle-counterfeit-medication-ring/
• WHO warning on counterfeit Darzalex in the Maldives (Edition.mv): https://edition.mv/news/52244
• Myanmar FDA warning on counterfeit Albutein (Global New Light of Myanmar): https://www.gnlm.com.mm/fda-crackdown-nationwide-warning-issued-over-counterfeit-albutein/
• Kenya PPB warning on counterfeit Phesgo (KDRTV): https://www.kdrtv.co.ke/news/ppb-warns-kenyans-over-fake-cancer-drug-in-circulation/
• UK death and rising adverse events linked to retatrutide (Daily Mail): https://www.dailymail.com/health/article-15940951/man-dies-unapproved-weight-loss-drug-Reta-76-injuries.html
• Australian warnings on fake retatrutide and liver failure (ABC News): https://www.abc.net.au/news/2026-06-20/liver-failure-fake-retatrutide-health-risk/106814372
• Australia’s TGA crackdown on unapproved peptides (ABC News): https://www.abc.net.au/news/2026-06-10/peptide-tga-regulation-crackdown/106781680
• New Zealand Medsafe consumer advisory on unapproved peptides: https://www.medsafe.govt.nz/safety/Alerts/Consumer-advisory-Unapproved-peptide-products-health-warning.asp
• Dutch hospitals warn of comas from counterfeit weight-loss drugs (NL Times): https://nltimes.nl/2026/07/01/dutch-hospitals-issue-warning-fake-weight-loss-drugs-cause-comas
• Malta warning on unauthorised weight-loss medication (Times of Malta): https://timesofmalta.com/article/health-authorities-warn-unauthorised-weight-loss-medication.1129843
• CBS News investigation into experimental weight-loss drug sales: https://www.cbsnews.com/projects/2026/experimental-weight-loss-drug/
• CBS News on retatrutide sold in New York bodegas: https://www.cbsnews.com/news/weight-loss-drug-retatrutide-unapproved-sales-convenience-store/
• Chainalysis on the grey-market peptide crypto economy: https://www.chainalysis.com/blog/gray-market-peptide-crypto-boom/
• Partnership for Safe Medicines, Q1 2026 peptide import analysis: https://www.safemedicines.org/2026/06/fishy-peptide-freight.html
• Puducherry counterfeit Pregabalin factory shut down (The Federal): https://thefederal.com/category/health/fake-medicine-tablet-pills-pondicherry-pudhucherry-counterfeit-250263
• Gurugram FDA busts spurious Telma-AM racket (DrugsControl): https://drugscontrol.org/news-detail.php?newsid=45439
• Delhi follow-up raid in Telma-AM case (DrugsControl): https://drugscontrol.org/news-detail.php?newsid=45457
• Uttarakhand STF busts spurious medicine factory in Bazpur (Medical Dialogues): https://medicaldialogues.in/news/industry/pharma/bogus-medicine-factory-using-reputed-pharma-brands-busted-in-uttarakhand-175394
• Meerut FSDA uncovers fake Evion 400 network (DrugsControl): https://drugscontrol.org/news-detail.php?newsid=45498
• Fake drug and steroid racket busted in Delhi’s Narela (Bilkul Online): https://bilkulonline.com/2026/07/29/fake-drug-steroid-racket-busted-in-narela-delhi-health-minister/
• Bail denied in fake Mounjaro case (Indian Express): https://indianexpress.com/article/cities/delhi/gurgaon-court-avi-sharma-fake-mounjaro-case-bail-rejected-10760179/
• Nigeria Customs intercepts fake NAFDAC-labelled medicines at Apapa (Leadership): https://leadership.ng/customs-seizes-fake-nafdac-labelled-expired-medicines-illicit-drugs-worth-n53-39bn-at-apapa-port/
• Onitsha drug market hands over ₦435m in fake and expired drugs (The Nation): https://thenationonlineng.net/onitsha-market-hands-over-n435m-fake-expired-drugs-to-nafdac/
• NAFDAC Public Alert 036/2026 on counterfeit Forxiga look-alikes (FirstWord Pharma): https://firstwordpharma.com/story/7763441
• Enugu alert on counterfeit Augmentin 625mg (Sahara Reporters): https://saharareporters.com/2026/06/18/enugu-health-ministry-issues-alert-over-counterfeit-augmentin-625mg-tablets-circulation
• Nigerian Senate advances counterfeit medicines bill (Premium Times): https://www.premiumtimesng.com/news/more-news/893969-senate-advances-bill-to-strengthen-fight-against-counterfeit-drugs-proposes-15-year-jail-term-for-offenders.html
• Liberia LMHRA seizes counterfeit medicines in Bong County (The New Dawn): https://www.thenewdawnliberia.com/lmhra-seizes-l400000-in-counterfeit-medicines/
• Massachusetts counterfeit pill conspirators sentenced (DOJ): https://www.justice.gov/usao-edva/pr/conspirators-sentenced-prison-using-darknet-marketplace-distribute-dangerous
• New York counterfeit pharmaceutical enterprise convictions (DOJ): https://www.justice.gov/usao-sdny/pr/two-defendants-convicted-engaging-massive-enterprise-distribute-fake-pharmaceuticals
• New Jersey fentanyl analogue and counterfeit pill sentencings (DOJ): https://www.justice.gov/usao-nj/pr/two-more-members-drug-trafficking-organization-sentenced-prison-fentanyl-analogue
• Louisiana forensic lab on counterfeit street tablets (Louisiana Radio Network): https://louisianaradionetwork.com/2026/07/09/47305/
• Alibaba DOJ settlement over illicit drug and pill press sales (Blockonomi): https://blockonomi.com/alibaba-baba-reaches-600m-doj-settlement-following-illegal-drug-sales-investigation/
• Pakistan approves nationwide track-and-trace system (APP): https://www.app.com.pk/national/federal-cabinet-approves-track-trace-system-nationwide-to-eliminate-counterfeit-medicines/
• Ukraine establishes national medicine verification organisation (Sud.ua): https://sud.ua/en/news/ukraine/366556-v-ukraini-zaprovadzhuiut-natsionalnu-systemu-veryfikatsii-likiv-iak-vona-pratsiuvatyme
• MHRA, ASA and GPhC joint warning on weight-loss medicine advertising (GOV.UK): https://www.gov.uk/government/news/warning-on-promoting-newly-licensed-prescription-only-medicines-and-unlicensed-medicines-for-weight-management
• MHRA updated botulinum toxin warnings (GOV.UK): https://www.gov.uk/government/news/updated-warnings-for-botulinum-toxin-products-following-rare-cases-of-botulism
• Four sentenced following MHRA Operation Lamborghini (GOV.UK): https://www.gov.uk/government/news/four-sentenced-to-nearly-15-years-combined-jail-time-following-major-mhra-investigation-into-illegal-online-supply-of-medicines
• UK experts warn of counterfeit weight-loss pill surge (iNews): https://inews.co.uk/news/health/fake-weight-loss-pills-chalk-paint-black-market-4627280
• MP questions MHRA capacity against counterfeit drugs (The Independent): https://www.independent.co.uk/news/uk/home-news/wegovy-pill-weight-loss-jab-mp-layla-moran-warning-mhra-b3004870.html
• Tajikistan shuts down counterfeit children’s medicines operation (Times of Central Asia): https://timesca.com/tajikistan-shuts-down-counterfeit-childrens-medicines-operation/
• Illicit online pharmacies research (Journal of Illicit Trade, Financial Crime, and Compliance): https://jitfccjournal.com/index.php/jitfcc/article/view/17

New partnership extends AI-powered counterfeit detection to medications used by tens of millions of patients annually, covering a combined market exceeding $5 billion

Helsinki 08JUN2026. TrueMed, the leader in AI-based pharmaceutical counterfeit detection, today announced a commercial partnership with one of the world’s ten largest pharmaceutical companies. The agreement brings TrueMed’s AI-powered authentication platform to three of the partner’s established antibiotic and anti-infective products, medicines already in wide circulation that are prescribed to an estimated 60 to 80 million patients globally each year.

The three drug franchises covered represent a combined global market value of more than $5 billion and are dispensed across primary care, pediatric, and hospital settings in over 100 countries. Because these products are already in the field across more than 100 countries, their packaging is actively being replicated by counterfeiters.

TrueMed’s core advantage is that no supply chain changes, new serialization codes, or product reformulation are required. The platform authenticates packaging against the original artwork files already on record, comparing them to what is reaching pharmacies and patients. For drugs that have been on the market for years, this means protection can be activated immediately, against a threat that has been growing just as long.

“When a top-10 global pharma company brings three of its most prescribed products to us for protection, it validates what we’ve built, and signals where the industry is heading. Patient safety starts now, with the product already on your shelves, not after months of manufacturing changes.”

Jyrki Berg – CEO, TrueMed

Counterfeit antibiotics represent one of the most dangerous segments of the $200 billion global counterfeit pharmaceutical market. The World Health Organization estimates that up to 10% of medicines in low- and middle-income countries are substandard or falsified, with antibiotics among the most frequently targeted drug classes. The consequences range from treatment failure and weakened antibiotic effectiveness to direct patient harm.

TrueMed starts with the source of truth: each product’s original artwork file. Every package in the field is measured against it, with discrepancies in typography, color, print registration, and layout flagged automatically. Deployment takes weeks, not months. Submissions are frictionless — photograph suspect packaging, submit via mobile app or secure web portal, and get results instantly. A confirmed counterfeit automatically opens a case record in TrueMed Case Management, where it is logged, tracked, routed to the right contacts, and ready to share with authorities.

With three of the world’s most prescribed anti-infective products now under TrueMed protection, patients and providers can trust that the medicine in hand is exactly what it claims to be.

About TrueMed.

TrueMed is a leading provider of anti-counterfeiting technology solutions. The company’s AI-enabled platform uses cutting-edge technology to analyze and identify potential counterfeit products, allowing companies to quickly and efficiently protect their brands and their customers.

For more information, please visit truemedinc.com.
Contact: Tuomas Kannas
TrueMed
tuomas.kannas@truemedinc.com

Counterfeit Medicine Roundup: May 2026

May was not a quiet month. From a global enforcement haul announced at the start of the month to five maternal deaths linked to fake oxytocin at the end of it, the news cycle delivered a steady stream of counterfeit medicine stories. What stood out was not just the volume. It was the variety. Antibiotics, antimalarials, oxytocin, rabies vaccines, cancer and liver drugs, weight-loss injectables, and fentanyl-laced pills all surfaced in seizures and investigations across at least four continents.

Here is what happened, and what it tells us about where the threat is heading.

Global enforcement scaled up

The month opened with the figures from INTERPOL’s Operation Pangea XVIII, which 90 countries used to target the online sale of illicit and counterfeit medicines. The operation produced 6.42 million seized doses worth roughly 15.5 million US dollars, 269 arrests, and the dismantling of 66 criminal groups. Investigators also took down around 5,700 websites, social media pages, and bots used to market fakes online. The UK led all countries by volume seized, followed by Colombia and Australia. The most commonly seized categories tell their own story: erectile dysfunction drugs, sedatives, painkillers, antibiotics, and anti-smoking products.

Africa featured heavily. Authorities in Burkina Faso intercepted 384,000 antibiotic capsules. In Cote d’Ivoire, officers pulled a full tonne of counterfeit ibuprofen from a single vehicle. Cameroon seized thousands of bottles of suspected fake antimalarials and antibiotics.

Days later, Europol announced one of the bigger network takedowns of the year. A coordinated action on May 12 ran 138 searches across Bulgaria, Greece, Hungary, Poland, Romania, and Moldova, with at least nine arrests. The criminal organization had operated for nearly two decades and moved an estimated 240 million euros in illicit transactions, much of it built on fake supplements sold to people with diabetes, cancer, and psoriasis through manipulative ads and fake endorsements. Investigators seized assets worth 17.7 million euros, identified a central warehouse in Bulgaria holding more than 300 types of illegally produced supplements, and blocked 196 selling websites in Romania.

The pattern across both operations is hard to miss. The web is now the storefront, and the criminals running it are organized, durable, and patient.

The WHO put the problem on the record

On May 13, the World Health Organization released a new toolkit warning that substandard and falsified medicines have become a major global health threat. The headline estimate is the one worth repeating: up to one in ten medicines sold in low- and middle-income countries may be substandard or falsified.

The WHO pointed to a familiar set of drivers. Medicine shortages, high treatment costs, weak regulation, and the rapid growth of online sales have opened the door for criminal networks, and that door swings wider during emergencies and outbreaks. The report singled out lifestyle and weight-loss drugs as especially common counterfeiting targets, and it stressed that fake medicines do more than fail to treat. They worsen illness, fuel antimicrobial resistance, and erode trust in health systems.

India had a brutal month

If one country dominated the counterfeit headlines in May, it was India, and the stories were among the most serious of the year.

The most devastating broke late in the month. In Kota, Rajasthan, five pregnant and postpartum women died at a government medical college hospital after surgery. Laboratory tests on the oxytocin injections administered during treatment reportedly found zero active oxytocin content. Oxytocin is used to control bleeding after childbirth, so a counterfeit version is not merely ineffective. It is lethal in exactly the moment a patient needs it most. Around 16,000 of the injections had been supplied across the state, and authorities seized 3,501 and banned the suspect batch as the investigation widened.

Earlier in the month, Delhi Police Crime Branch busted a counterfeit drug racket worth close to 10 crore rupees, arresting four people who were allegedly manufacturing fake versions of expensive cancer and liver disease medicines and distributing them across multiple states.

A second Delhi operation exposed how deep the supply chain rot can run. An interstate syndicate was caught diverting genuine government-supply medicines out of Uttar Pradesh, stripping the original labels, and relabeling them for resale. The haul included counterfeit rabies vaccines, hepatitis B vaccines, insulin, human albumin, snake venom anti-serum, and cancer drugs. These are the medicines patients reach for in emergencies, which makes a fake one a quiet catastrophe.

Africa’s open-market problem stayed in focus

Nigeria’s Pharmacy Council reported sealing 1,550 pharmacies, patent medicine shops, and illegal outlets across Kano, Kaduna, and Nasarawa in a sweep that ran into mid-May. Kano alone accounted for 821 sealed premises. Regulators tied the crackdown to the country’s persistent burden of counterfeit and substandard antibiotics, antimalarials, and controlled substances sold through unregulated channels, and to the antimicrobial resistance that follows.

The trade dimension got attention too. In early May, the Office of the US Trade Representative flagged Kenya as a key destination and transit point in the global counterfeit goods network, pharmaceuticals included. The report described fakes shipped from manufacturing hubs through transit countries with weak enforcement, and a tactical shift worth noting: criminals are increasingly using small parcels sent through courier and postal services rather than large, easy-to-intercept shipments. The USTR cited an estimate that between 9 and 41 percent of medicines in low- and middle-income countries may be counterfeit.

The GLP-1 and pill-press fronts in the US

In the United States, two threads ran in parallel.

The Partnership for Safe Medicines published a May update on the weight-loss drug market, and the timing matters. The FDA approved two oral GLP-1 treatments in April, which the group expects will draw in patients who avoided injections and spawn a fresh wave of counterfeits. Fakes of semaglutide and tirzepatide products have already turned up in dozens of countries, sold through unregulated websites, gray-market peptide vendors, and med spas with thin oversight. The harm is no longer theoretical. The update points to hospitalizations, a liver transplant, and lawsuits tied to compounded and black-market versions.

On the pill-press front, lawmakers in Florida backed the PRESS Act in early May, aimed at restricting the machines used to stamp out counterfeit pills. The context is the overdose crisis: counterfeit pills laced with fentanyl and other synthetics continue to kill, often when a buyer believes they are taking something else entirely.

The through-line

Read across all of it and a clear shape emerges. Counterfeiters are not picking one lane. In a single month the fakes ranged from cheap antibiotics to oral cancer drugs, from maternal injectables to designer weight-loss pens. The selling has moved online and into small parcels that slip past traditional border checks. And the criminal networks behind it are organized enough to run for twenty years and generate hundreds of millions in revenue.

The common denominator is the gap between a patient and proof. When a package looks genuine, when a website looks legitimate, when a vial carries the right label, the patient has no way to know. Closing that gap is the entire point of brand protection and product authentication. Every story above is a story about a moment where a patient, a pharmacist, or a regulator could not tell the real from the fake fast enough.

That is the problem TrueMed exists to solve. The volume and variety on display this May are exactly why authentication cannot be left to patients, clinicians, or caregivers to know what to look for. The fakes are too convincing and the categories too broad for the human eye to be the last line of defense. It requires AI-assisted verification that confirms a product as genuine in seconds, from the artwork alone, with no special equipment and no change to the supply chain. That is how you close the gap between a patient and proof, and put a real answer in the hands of the people who need it most, wherever they are.

Sources

• INTERPOL, Operation Pangea XVIII global results: https://www.interpol.int/en/News-and-Events/News/2026/Global-crackdown-on-illicit-pharmaceuticals-sees-USD-15.5-million-in-seizures
• Europol counterfeit medicine network takedown (Brussels Times): https://www.brusselstimes.com/eu-affairs/2138472/europol-helps-dismantle-e240m-counterfeit-medicine-network-across-europe
• WHO report on fake medicines and online sales (Devdiscourse): https://www.devdiscourse.com/article/health/3902959-fake-medicines-and-online-drug-sales-pose-major-risks-warns-new-who-report
• Kota fake oxytocin deaths (Republic World): https://www.republicworld.com/india/zero-oxytocin-content-found-in-injections-given-to-pregnant-women-probe-deepens-into-kota-deaths-2026-05-27-125855
• Kota deaths linked to suspected fake oxytocin (CSR Journal): https://thecsrjournal.in/pregnant-women-deaths-kota-linked-suspected-fake-oxytocin-batch/
• Delhi fake cancer and liver drug syndicate (Medical Dialogues): https://medicaldialogues.in/news/industry/pharma/delhi-police-busts-rs-10-crore-syndicate-supplying-fake-cancer-liver-disease-drugs-4-held-170252
• Delhi fake rabies vaccine racket (The420): https://the420.in/interstate-fake-vaccine-racket-busted-counterfeit-rabies-shots-delhi-ncr/
• Delhi fake life-saving medicine racket (Economic Times): https://economictimes.indiatimes.com/news/india/fake-life-saving-medicine-racket-busted-in-delhi-heres-how-they-repackaged-and-sold-drugs-across-several-states/articleshow/130958153.cms
• Nigeria Pharmacy Council seals 1,550 outlets (Punch): https://punchng.com/1550-fake-medicine-outlets-shut-in-kano-kaduna-nasarawa/
• Kano fake drug seizure (Punch): https://punchng.com/kano-seizes-n200m-fake-drugs-vows-crackdown-on-unapproved-medicines/
• US lists Kenya among key fake-medicine markets (Business Daily Africa): https://www.businessdailyafrica.com/bd/economy/us-lists-kenya-among-key-markets-for-fake-medicines-5447566
• GLP-1 safety update (Partnership for Safe Medicines): https://www.safemedicines.org/2026/05/glp-1-safety-risks-may-2026.html
• Florida PRESS Act targeting counterfeit pill manufacturing (NBC Miami): https://www.nbcmiami.com/news/local/new-bill-seeks-to-prevent-overdose-deaths-by-targeting-counterfeit-pill-manufacturing/3805038/
• CDSCO April drug quality test results (The420): https://the420.in/cdsco-april-drug-quality-tests-spurious-medicine-patient-safety/
• Illegal fake medicine factory sealed in Uttarakhand (ThePrint): https://theprint.in/india/illegal-factory-producing-fake-medicines-sealed-in-uttarakhands-kotdwar/2939804/
• 1 in 5 tricked into buying fake medications (ClickOnDetroit): https://www.clickondetroit.com/video/news/2026/05/12/1-in-5-people-tricked-into-buying-fake-medications/
• Call for curbs on e-pharmacies (Deccan Chronicle): https://www.deccanchronicle.com/southern-states/andhra-pradesh/call-for-curbs-on-e-pharmacies-1956360
• Chemists warn of discount-led fake medicines and online pharmacies (Telegraph India): https://www.telegraphindia.com/west-bengal/kolkata/chemists-warn-of-discount-led-fake-medicines-and-rise-in-illegal-online-e-pharmacies-prnt/cid/2161419
• Track-and-trace delays leave patients vulnerable (Minute Mirror): https://minutemirror.com.pk/public-exposed-track-trace-system-delays-leave-patients-vulnerable-to-fake-drugs-559480/
• Malaysia’s legal blind spots on counterfeit medicines (Muslim Network TV): https://www.muslimnetwork.tv/malaysias-legal-blind-spots-helping-counterfeit-medicines-survive/

What March and April 2026 Showed Us

Two months of headlines, one consistent message: counterfeit pharmaceutical activity is accelerating across every region, every therapeutic category, and every distribution channel. From a landmark global investigation into fake cancer drugs infiltrating hospital supply chains to record-breaking fentanyl pill press sentences in the United States, March and April made clear that the threat is not confined to informal markets or developing economies. It is systemic.

United States: Sentencing, Seizures, and Supply Chain Fraud

Safe Chain Solutions: A Landmark Sentence

Charles and Patrick Boyd, co-owners of Safe Chain Solutions, received 20 and 18 years in federal prison respectively for counterfeit drug crimes and wire fraud. The Cambridge, Maryland-based distributor was at the center of a diversion ring that sold U.S. pharmacies over 85,000 counterfeit bottles of secondhand HIV medicine worth more than $250 million. This is one of the largest counterfeit drug cases in recent US history by both volume and dollar value.

Sources: PSM: Safe Chain sentence analysis  |  PSM: March 17, 2026 roundup

Counterfeit Oncology Drugs

Separately, 45-year-old Indian national Sanjay Kumar received a 43-month federal prison sentence for conspiring to sell counterfeit Keytruda to undercover law enforcement agents between 2018 and 2024. The fake versions he sold did not contain enough active ingredient to be effective.

Sources: PSM: March 10, 2026 — Fake cancer drug distributor sentenced

Fentanyl Pill Presses: Escalating Sentences

A Spokane, Washington man was sentenced to 20 years in prison for running a fentanyl pill press operation. A North Carolina man found with fentanyl pills and a pill press received a 35-year federal sentence for sex trafficking.

A South Carolina man was sentenced to 25 years in federal prison for manufacturing hundreds of thousands of counterfeit pills laced with fentanyl. Authorities seized 150,000 pills made to look like Roxicodone, 30 kilograms of fentanyl, pill stamps, and pill binders during the investigation.

Sources: PSM: March 10, 2026  |  PSM: April 27, 2026

Operation Spring Cleaning and Related Seizures

Florida authorities arrested 19 people as part of Operation Spring Cleaning, seizing 183.5 kilograms of counterfeit pills and over ten kilograms of other illicit drugs. Three California men were separately indicted on drug trafficking charges after the US Postal Service intercepted over 100 packages containing controlled substances, leading to the discovery of three pill presses and pill-making materials in a warehouse.

Sources: PSM: April 13, 2026

FDA Satellite Labs

The FDA highlighted its network of scientists at major mail facilities across the country who use advanced chemical analysis to detect and intercept dangerous, counterfeit, and illegal drugs before they reach consumers. The program is expanding to new locations including Honolulu to strengthen monitoring of Pacific-region imports.

Sources: PSM: April 20, 2026

United Kingdom: Weight-Loss Drug Fraud Deepens

The MHRA warned patients about counterfeit Mounjaro KwikPen injection pens dispensed by a private online clinic in Birmingham. Although testing confirmed the fakes contain tirzepatide, their manufacturing conditions are unknown, raising concerns about sterility and potential infection or allergic reactions.

The MHRA also raided two premises in England, disrupting a second facility suspected of manufacturing and distributing unlicensed retatrutide. Officers seized nearly 2,000 doses of unauthorized products, including manufacturing equipment, pharmaceutical ingredients, and packaging materials.

UK researchers found that cybercriminals are increasingly cloning legitimate online pharmacy websites and social media accounts to sell counterfeit weight-loss medications, often copying official regulator logos to appear trustworthy. The National Pharmacy Association suggested the government consider allowing pharmacies to use a dedicated domain such as pharmacy.uk to help patients identify regulated providers.

The MHRA also warned the public about counterfeit Viagra-style pills after working with eBay to remove 215 illegal online listings.

Sources: GOV.UK: Fake Mounjaro KwikPen warning  |  PSM: March 2, 2026 — MHRA raids  |  PSM: April 20, 2026 — Cloned pharmacy websites  |  PSM: April 13, 2026 — Counterfeit Viagra listings

Europe: Operation SHIELD VI Results Published

Results from Europol’s Operation SHIELD VI — which ran from April to November 2025 — were published in early March. The operation led to 3,354 prosecutions and the seizure of €33 million worth of counterfeit medicines and illegal supplements across 30 countries. It exposed how organized crime networks exploit growing demand for weight-loss drugs, performance enhancers, and recreational substances, including counterfeit semaglutide products and fake drugs containing dangerous synthetic substances like nitazenes.

The delayed publication of these results matters for brand protection teams. Operations of this scale take months to conclude, prosecute, and report. The counterfeit infrastructure that SHIELD VI dismantled was already well established by the time enforcement acted.

Sources: Europol: Operation SHIELD VI results  |  PSM: March 2, 2026

Asia: Philippines, India, and Vietnam

Philippines: Keytruda Seizure and China Smuggling

Filipino authorities arrested four suspects in Makati City after seizing approximately ₱102.5 million worth of counterfeit cancer drugs labeled as Keytruda during a sting operation. Separately, the Bureau of Customs in Manila seized over ₱53 million worth of counterfeit drugs shipped from China that were falsely declared as pet cages.

Sources: PSM: April 13, 2026 — Philippines seizures

India: Fake Mounjaro and Counterfeit Oncology Networks

Indian authorities seized ₹56 lakh of counterfeit Mounjaro injections and arrested two people. Eli Lilly confirmed it would assist in the investigation and support regulatory action.

Delhi Police also busted a large counterfeit medicine racket involving fake diabetes drugs and painkillers falsely branded under major pharmaceutical companies, arresting six people after uncovering a factory, storage sites, and a fraud network.

Sources: PSM: April 20, 2026 — India Mounjaro seizure  |  PSM: April 13, 2026 — Delhi Police bust

Vietnam

Police in Vietnam dismantled a counterfeit medicine ring that produced and sold fake traditional drugs mixed with paracetamol, arresting three suspects in the operation.

Sources: PSM: April 20, 2026 — Vietnam ring dismantled

Pakistan and Saudi Arabia: Regulatory Alerts

Pakistan’s Drug Regulatory Authority issued an emergency alert after six commonly used medicines in Punjab were found to be counterfeit or substandard, warning the public to stop using them immediately due to serious health risks.

Saudi Arabia’s Ministry of Health detained multiple gym trainers for promoting and selling unregistered peptides and hormonal drugs. Monitoring of social media by the Saudi Food and Drug Authority led investigators to a warehouse storing the drugs, including retatrutide. Officials raised concerns about improper storage conditions and urged the public to obtain drugs only through legitimate supply chains.

Sources: PSM: April 27, 2026 — Pakistan alert  |  PSM: April 6, 2026 — Saudi Arabia gym trainers

Canada: Peptide Warning

Health Canada warned the public against using unauthorized injectable peptide drugs sold online, noting they have not been assessed for safety, quality, or effectiveness. The agency advised Canadians to obtain prescription medications only from licensed pharmacies, as many products available through unregulated online channels may be contaminated, mislabeled, or dangerous.

Sources: PSM: April 20, 2026 — Health Canada peptide warning

Consumer Behavior: New Research Confirms the Scale

A Michigan State University study published in late April added important context to enforcement data. Researchers surveying nearly 5,000 participants across eight countries found that one in five consumers has been deceived into buying counterfeit medicines, while one in four has knowingly purchased them.

The study also found that social norms strongly influence purchase behavior — consumers who believed their close family and friends accepted counterfeit purchases were significantly more likely to buy them, both intentionally and unintentionally.

For brand protection teams, this matters. Enforcement removes product from circulation. It does not change the conditions that drive demand toward unverified sources.

Sources: MSU Today: 1 in 5 consumers deceived into buying fake meds

Where This Leaves Brand Protection Teams

March and April reinforced two things.

First, counterfeit activity is now firmly embedded in premium therapeutic categories — oncology, GLP-1s, injectable aesthetics. These are not low-margin targets. They are high-visibility, high-demand products with global patient populations and deeply asymmetric pricing. The combination creates sustained criminal incentive that enforcement alone cannot eliminate.

Second, the distribution channels have diversified beyond seizure capacity. Cloned pharmacy websites, social media resale, master carton smuggling, and domestic compounding fraud are all operating in parallel. Each channel requires a different detection approach.

Brands in high-risk categories cannot wait for enforcement to surface the threat. The question is how quickly exposure can be identified and validated before harm scales.

Primary sources: ICIJ, Partnership for Safe Medicines, Europol, MHRA, GOV.UK, NAFDAC, US DOJ, FDA, CBP, TheDiggerNews, Yucatan Times, MSU Today

Counterfeiting is no longer a series of isolated incidents. It is organized, adaptive, and often global. As fake products become harder to spot and faster to replicate, brand protection teams need better ways to connect the dots between what they are seeing in the field. This is where counterfeit strain analysis comes in.

At its core, strain analysis applies AI and machine learning techniques to group counterfeit products that likely share a common origin. Instead of treating each fake as a one-off problem, strain analysis looks for patterns across artworks to identify groups of counterfeits that may be coming from the same source or network.

From Clustering to Strain Analysis

In data science, clustering is a machine learning technique used to group similar objects or data points together based on shared characteristics or patterns. Counterfeit strain analysis builds on this idea by applying clustering specifically to counterfeit products. The goal is not just to say that two items look alike, but to assess whether they are likely connected through shared production methods, suppliers, or criminal operations.

This shift in perspective changes how brands respond to counterfeiting. Instead of playing whack a mole with individual takedowns, strain analysis helps teams understand how counterfeit operations are structured and how they evolve over time.

The Real World Benefits of Counterfeit Strain Analysis

When strain analysis is applied consistently, it unlocks a set of strategic benefits that go well beyond basic detection.

Revealing organized operations across markets

Finding the same or highly similar counterfeit artwork in different regions often signals larger or even international criminal organizations. Strain analysis makes these patterns visible, helping teams recognize when they are dealing with coordinated networks rather than isolated bad actors.

Understanding regional and global counterfeit activity

By grouping counterfeits into distinct strains, brands can better understand how counterfeit activity differs by geography. This allows teams to see where certain strains are spreading, which regions are being targeted, and how tactics differ from one market to another.

Identifying new variants and linking to past investigations

Counterfeiters frequently change small details in their packaging or products to avoid detection. Strain analysis helps identify when a counterfeit represents a new variant of an existing strain and whether it can be linked back to previous cases. This continuity is critical for building stronger investigative narratives over time.

Tracking how counterfeiters evolve their methods

Bad actors often upgrade their artwork or packaging, but they tend to reuse or conserve certain elements from earlier versions. Strain analysis can surface these shared elements across different counterfeit groups, revealing how operations evolve while still leaving behind recognizable fingerprints.

Connecting counterfeit activity across different products

In many cases, the same counterfeit operation is responsible for fakes across multiple products or brands. Strain analysis helps identify these cross-product patterns, giving brands a clearer view into how individual counterfeiters operate and diversify their efforts.

Informing packaging and product development

Strain analysis can also feed back into prevention. By identifying which packaging components or security features are most frequently exploited or mimicked in the field, brands can make more informed decisions about where their current protections are failing and where future improvements should focus.

Moving From Incidents to Intelligence

The biggest shift strain analysis enables is moving from incident response to intelligence driven brand protection. Instead of simply reacting to counterfeit finds, teams can begin to map counterfeit ecosystems, prioritize the most impactful threats, and align enforcement, legal, and packaging strategies around real patterns in the market.

Over time, as more data is collected and more counterfeit samples are analyzed, strain analysis becomes more powerful. The insights compound. Patterns become clearer. And brand protection efforts become more proactive, targeted, and effective.

Why This Matters Now

Counterfeiting is becoming more sophisticated, not less. As counterfeiters adopt better printing, manufacturing, and distribution tactics, brands need equally sophisticated tools to keep up. Counterfeit strain analysis offers a way to see beyond individual fakes and start understanding the operations behind them.

For brand protection teams, that shift in visibility can be the difference between chasing symptoms and disrupting the source.

What February 2026 Showed Us

If February proved anything, it is this: counterfeit pharmaceutical activity is not isolated, not regional, and not slowing down. From large-scale online pharmacy takedowns to fake GLP-1 injectables circulating in major markets, enforcement activity spanned nearly every continent. What we are seeing is not opportunistic crime. It is structured, repeatable, and increasingly sophisticated.

Here is what stood out this month and why it matters for brand protection teams responsible for protecting both revenue and patient safety.

Illegal Online Pharmacies: A Global Infrastructure Problem

The DEA’s Operation Meltdown resulted in the seizure of hundreds of illegal online pharmacy domains connected to a transnational criminal network. These were not small operations. They were structured, professional, and designed to look legitimate to consumers searching for convenience or lower prices.

Investigations continue to show how these sites mimic real pharmacies, use payment processing tools that appear compliant, and exploit supply shortages to drive urgency. The infrastructure behind them is agile, which means domains can disappear and reappear quickly under new names.

Links:

https://www.dea.gov/press-releases/2026/02/04/dea-operation-meltdown-shuts-down-hundreds-illegal-online-pharmacies

https://www.pharmacy.biz/india-illegal-online-pharmacies

For brands, this reinforces a hard truth. Shutting down websites is necessary, but preventing counterfeit product from being trusted in the first place is what ultimately reduces harm.

Europe: Coordinated Enforcement Is Expanding

Europol’s Operation SHIELD VI led to hundreds of prosecutions and millions of euros in seized illicit medicines. Austrian customs and other authorities intercepted large volumes of counterfeit pills moving across borders, demonstrating growing cross-agency coordination.

The operation targeted not only finished counterfeit medicines but also trafficking networks, doping substances, and organized pharmaceutical crime rings operating across EU member states.

Links:

https://www.europol.europa.eu/media-press/newsroom/news/3354-individuals-prosecuted-in-europol-coordinated-hit-against-pharmaceutical-crime-networks

https://www.visahq.com/news/2026-02-25/at/austrian-customs-help-seize-31-million-counterfeit-pills-in-eu-wide-shield-vi-operation

Encouraging as these actions are, most seizures happen after product has already entered circulation. Earlier identification remains the missing link.

GLP-1 and Weight-Loss Drugs: Demand Driving Risk

Regulators in the UK issued warnings about fake Mounjaro pens, while investigations tied to counterfeit Ozempic and similar injectables continue. Media outlets are now publishing consumer advice on how to identify scams, which shows that the issue has moved into mainstream awareness.

GLP-1 therapies sit at the intersection of high price, high demand, and limited supply. That combination creates ideal conditions for counterfeiters. Social media resale channels and informal online marketplaces are amplifying the risk.

Links:

https://www.gov.uk/government/news/fake-mounjaro-tirzepatide-kwikpen-15mg-pre-filled-pens

https://www.msn.com/en-gb/news/uknews/london-police-hunt-woman-over-32-000-haul-of-fake-weight-loss-drugs-ozempic-and-mounjaro/ar-AA1LxrW7

https://www.thesun.co.uk/health/38334494/spot-fat-jab-scam-tips-black-market

For brand owners in this category, proactive monitoring and product-level verification are foundational to protecting patients and preserving trust.

North America: Counterfeit Pills and Hidden Ingredients

In the United States, authorities reported large counterfeit pill seizures tied to regional drug busts. These cases often involve pills pressed to resemble known brands but containing entirely different substances.

At the same time, regulatory alerts continue to surface around dietary supplements adulterated with undisclosed prescription ingredients. Consumers may believe they are purchasing safe over-the-counter products when in fact they are exposed to potent pharmaceuticals.

Links:

https://fox59.com/news/indynews/3-arrested-688000-in-counterfeit-pills-seized-in-tippecanoe-county-drug-bust

https://www.msn.com/en-us/health/nutrition/counterfeit-dietary-supplement-tainted-with-drug-used-to-treat-ed-warns-fda/ar-AA1WpCCc

https://www.insauga.com/fake-ozempic-like-drugs-flooding-canada-pose-a-serious-danger-feds-report

Counterfeit risk today is as much about composition as it is about packaging. Wrong ingredients and incorrect dosing create direct patient safety threats.

India: Manufacturing and Distribution Networks Exposed

Multiple enforcement actions across India uncovered counterfeit factories, fake packaging operations, and interstate supply chains distributing lookalike medicines. Reports described seized tablets, packaging materials, and coordinated logistics moving product across state lines.

These were not isolated incidents. They reflect repeatable production models capable of scaling quickly when demand exists for a targeted product.

Links:

https://pioneeredge.in/fake-medicines-racket-police-arrests-another-accused

https://www.hindustantimes.com/india-news/massive-counterfeit-himalaya-drugs-gang-busted-in-ghaziabad-police-reveal-two-state-modus-operandi-101770605682706.html

https://dailypioneer.com/news/police-bust-second-fake-medicine-factory-in-bihar-total-9-arrested

https://indianexpress.com/article/cities/delhi/delhi-police-antf-fake-medicine-factory-gaya-bihar-tramadol-seizure-arun-arrest-10532587

https://medicaldialogues.in/news/industry/pharma/fake-telma-am-racket-busted-in-thane-two-pharma-distributors-arrested-165020

When counterfeiters can source packaging, replicate labeling, and distribute at scale, visual inspection alone becomes unreliable.

Africa: Sustained Pressure on High-Risk Medicines

In Nigeria, NAFDAC dismantled major drug warehouses containing large volumes of fake medicines. Public commentary continues to call for stronger enforcement across the region, particularly in high-risk categories such as oncology.

In Kenya, editorials stressed the urgency of eliminating counterfeit cancer drugs. In critical therapies, counterfeit exposure can directly impact survival outcomes.

Links:

https://saharareporters.com/2026/02/10/nafdac-dismantles-lagos-drug-warehouses-seizes-fake-medicines-worth-over-n10billion

https://www.standardmedia.co.ke/editorial/article/2001541007/rid-kenya-and-africa-of-counterfeit-cancer-drugs

For global brands operating in these markets, monitoring cannot be limited to primary distribution channels.

Where This Leaves Brand Protection Teams

The common thread across these headlines is scale and persistence. Counterfeiters are operating across channels, across borders, and across therapeutic categories.

Enforcement will continue, and cooperation between agencies is improving. Long-term deterrence depends on earlier detection, faster validation, and evidence that stands up in legal and regulatory environments.

For brands, the question is no longer whether counterfeit exposure exists. The question is how quickly it can be identified and proven before it spreads.